CHICAGO- BCDI’s team of expert physicians and research specialists spent April 4 – 6 at the Thrombosis & Hemostasis Summit of North America (THSNA) presenting cutting edge research and programming across various bleeding and clotting disorders.

BCDI Associate Medical Director/Associate Research Director Dr. Jonathan Roberts, Staff Physician Dr. Jessica Mistretta, Senior Research Coordinator Shayla Nunn and Research Associate/Data Manager Nikki Barclay presented six research posters/exhibits regarding research done at BCDI. Research topics included:

  • Evaluation of real-world treatment patterns and outcomes in patients with Von Willebrand Disease treated prophylactically with recombinant Von Willebrand Factor across treatment centers in the United States.
  • Structured education for newly diagnosed persons with Von Willebrand Disease: a Hemophilia Treatment Center quality improvement project abstract.
  • Efficacy and safety of Eptacog beta for bleed treatment in adults and adolescents with Hemophilia B and inhibitors during PERSEPT 1.
  • Prophylactic or post-traumatic treatment of hypofibrinogenemia and dysfibrinogenemia with Fibryga in eight clinical cases.
  • Emicizumab for severe Von Willebrand Disease and VWD/Hemophilia A: The EMIVWD Study.
  • Design of a prospective, observational, mulit-center study of the effectiveness of Efanesoctocog Alfa on long-term joint health in patients with Hemophilia A in the United States and Japan.

In a live-event session at THSA, Dr. Roberts also led a presentation entitled “Real-world experiences with ALTUVIIIO [Antihemophilic Factor (Recombinant), Fc- Von Willebrand Factor XTEN Fusion Protein]: A first-in-class treatment option.”